High-Concentration mAbs Present Manufacturing Challenges as Demand Surges, Reports CPHI Europe
Key Insights
FDA data shows 76% of approved monoclonal antibodies now have high-concentration formulations, reflecting a significant shift in therapeutic development trends.
The rise in subcutaneous therapeutics is driving demand for high-concentration mAbs, offering benefits like self-administration and reduced healthcare facility time.
Manufacturing challenges, particularly in sterile and tangential flow filtration, are prompting new developments in membrane technology and processing optimization.
The landscape of monoclonal antibody (mAb) manufacturing is experiencing a significant transformation, with high-concentration formulations becoming increasingly prevalent in approved therapeutics. According to Antonio Pierno, senior manager of Scientific Laboratory Services at Cytiva (search), 76% of FDA-approved mAbs now feature high-concentration formulations, marking a notable shift in pharmaceutical development.
Market Trends and Therapeutic Evolution
The industry is witnessing a marked transition toward subcutaneous therapeutics, moving away from traditional intravenous administration. This shift is primarily driven by practical advantages, including patient self-administration capabilities and reduced time and costs associated with healthcare facility visits. These subcutaneous formulations necessitate high-concentration therapeutics due to volume constraints in injection delivery.
High-concentration biologics are characterized by final concentrations exceeding 100g/L, with some manufacturers pushing boundaries to achieve concentrations as high as 250g/L. This trend is partially fueled by the growing demand for biosimilar reformulation.
Notable High-Concentration Products
Several prominent high-concentration biologics have already established their presence in the market, including:
- Cosentyx (secukinumab) by Novartis, targeting IL-17A
- Xolair (omalizumab) from Genentech and Novartis
- Dupixent (dupilumab) by Sanofi/Regeneron Pharmaceuticals, targeting IL-4/IL-13
Manufacturing Challenges and Solutions
The primary challenges in high-concentration therapeutic manufacturing center around sterile filtration and tangential flow filtration (TFF). These processes can lead to:
- Increased product viscosity
- Extended processing times
- Formation of aggregates
- Higher unit volume costs
- Reduced processing efficiency
To address these challenges, industry experts emphasize the importance of optimizing TFF parameters and developing new cassette technologies to enhance recovery procedures. Membrane selection plays a crucial role in the successful manufacturing of high-concentration mAbs.
Future Developments
The industry is focusing on developing new sterile filters specifically designed for high-concentration mAbs, with the primary objectives being:
- Maximizing membrane area
- Enhancing filtration processes
- Maintaining product quality
- Reducing production costs
Success in this area requires a thorough understanding of high-concentration mAb characteristics, including viscosity and flux properties, through comprehensive preliminary studies. These developments are essential for meeting the growing demand for high-concentration therapeutic products while ensuring efficient and cost-effective manufacturing processes.